

Pao to head drugs research at Roche

March 8, 2018 | News

Pao, now head of the oncology discovery and translational area for pRED, assumes his new role on April 2.



Swiss drugmaker Roche has named U.S. cancer expert William Pao head of its Pharma Research and Early Development (pRED) business after John Reed decided to leave for certain personal reasons.

Pao, now head of the oncology discovery and translational area for pRED, assumes his new role on April 2.

Pao joined Roche pRED in May 2014 as Global Head of Oncology.

He came to Roche pRED from Vanderbilt University Medical Center, where he was Professor of Medicine, Director of the Division of Hematology and Oncology, and Director of Personalized Cancer Medicine.

He also played leadership roles across a number of other departments, including Cancer Biology and Pathology/Microbiology/Immunology. He was previously a faculty member at Memorial Sloan-Kettering Cancer Center in the Human Oncology and Pathogenesis Program. William earned his MD and PhD degrees from Yale University, where he investigated the role of gamma-delta T cells in mice.

William and his research team have contributed to over 170 publications in fields including cancer biology, cancer genomics and cancer treatment.